Next-Generation GLP-1 Drugs in the Pipeline: What Is Coming After Tirzepatide

The weight-loss and diabetes drug landscape is evolving fast. Several next-generation therapies — including triple hormone agonists, oral GLP-1 pills, and amylin combination drugs — are already in Phase 2 or Phase 3 trials. Some could reach FDA review as early as 2026, potentially offering greater weight loss, better tolerability, or more convenient dosing than current options like Ozempic, Wegovy, or Mounjaro.

Why Do We Need Something Beyond Tirzepatide?

Tirzepatide (Mounjaro, Zepbound) already represents a major step forward by targeting both GLP-1 and GIP receptors simultaneously. In the SURMOUNT-1 trial, participants lost up to 22.5% of body weight — more than any previously approved obesity medication (Jastreboff AM et al., SURMOUNT-1, NEJM, 2022). Yet real-world challenges remain:

• Injectable format: Many people prefer or require a pill-based option.
• Side effect burden: Nausea, vomiting, and constipation cause some patients to discontinue.
• Weight-loss ceiling: A meaningful portion of users do not reach the 15–20% threshold.
• Cardiovascular and kidney outcomes: Researchers are still exploring which mechanisms most powerfully reduce organ-level risk.

Next-generation compounds aim to address each of these gaps through new delivery methods, additional hormone targets, or smarter dosing strategies.

What Are the Most Promising Drugs in the Pipeline?

Retatrutide (Triple GIP/GLP-1/Glucagon Agonist)

Developed by Eli Lilly, retatrutide adds glucagon receptor activation to the GIP and GLP-1 dual action already found in tirzepatide. In a Phase 2 trial published in The Lancet (Frias JP et al., 2023), participants taking the highest dose lost an average of 24.2% of body weight over 48 weeks — the largest figure ever reported in a Phase 2 obesity trial at that time. Retatrutide has since entered Phase 3 trials under the program name TRIUMPH.

CagriSema (Semaglutide + Cagrilintide)

CagriSema combines semaglutide (the active ingredient in Ozempic and Wegovy) with cagrilintide, a long-acting amylin analogue. Amylin is a hormone released alongside insulin that slows gastric emptying and reduces appetite through a different brain pathway than GLP-1. Phase 2 data (Enebo LB et al., Lancet, 2021) showed the combination produced greater weight loss than either drug alone. Novo Nordisk is now running a large Phase 3 program called REDEFINE, with results expected by late 2025 or 2026.

Oral Semaglutide 50 mg (Rybelsus Upgrade)

A higher-dose oral formulation of semaglutide is already showing strong results. The OASIS 1 trial (Knop FK et al., NEJM, 2023) found that 50 mg oral semaglutide produced about 15.1% weight loss over 68 weeks — comparable to injectable Wegovy 2.4 mg. Novo Nordisk submitted this formulation for FDA approval under the brand name Wegovy Oral, making it potentially the first oral GLP-1 drug approved specifically for obesity.

Orforglipron (Oral Small-Molecule GLP-1)

Unlike oral semaglutide, which is a peptide that requires a special absorption enhancer, orforglipron (Eli Lilly) is a small-molecule GLP-1 receptor agonist — meaning it can be swallowed like a typical pill without food or water restrictions. Phase 2 results showed up to 14.7% weight loss over 36 weeks, and Phase 3 trials are ongoing.

Mazdutide and Pemvidutide

These dual GLP-1/glucagon agonists are in active Phase 2 and Phase 3 development (by Innovent Biologics and Altimmune, respectively). Pemvidutide has attracted attention for potentially preserving more lean muscle mass compared to GLP-1-only agents — a meaningful concern given that current obesity drugs can reduce both fat and muscle.

How Do These Drugs Compare on a Development Timeline?

What Do These Advances Mean for People Already on GLP-1 Medications?

If you are currently taking Ozempic, Wegovy, Mounjaro, or Zepbound, the pipeline does not mean you should wait or stop. These drugs are proven, FDA-approved, and working for many people right now. What the pipeline does suggest:

• Oral options will likely expand: If injections are a barrier for you, affordable oral GLP-1 pills could become available within a few years.
• Higher weight-loss targets may become realistic: Triple agonists and combination therapies may push average results closer to what bariatric surgery achieves.
• Muscle preservation may improve: Newer formulations like pemvidutide are being specifically designed to reduce fat while protecting lean body mass.
• Competition may lower costs: As more agents enter the market, pricing pressure on existing drugs tends to increase.

The SELECT trial (Lincoff AM et al., NEJM, 2023) already demonstrated that semaglutide reduces major cardiovascular events. Researchers expect next-generation drugs will be studied for similar — and potentially broader — organ protection outcomes.

Are There Any Concerns About Next-Gen GLP-1 Drugs?

More powerful does not always mean better for every patient. Areas researchers and regulators are watching carefully include:

• Nausea and GI side effects: Triple agonists may carry a higher side-effect burden at effective doses.
• Muscle loss: Higher weight loss rates could mean more lean tissue lost alongside fat, which matters for older adults and people with low muscle mass.
• Long-term safety data: Newer compounds have shorter track records. Post-market surveillance will be critical.
• Access and cost: Next-generation drugs will likely launch at premium prices before any generic or biosimilar competition develops.

Frequently Asked Questions

The pipeline for GLP-1 and next-generation metabolic drugs is genuinely exciting, but individual treatment decisions should always be guided by a healthcare provider who knows your full medical history. If you are interested in whether an upcoming drug might be right for you, or whether a current therapy makes sense in the meantime, speak with your prescriber or an obesity medicine specialist. Clinical trial participation is also worth asking about — it is one way to access pipeline therapies before they are approved.